Latest pharmaceutical industry Stories
Lucintel profiles leaders in generic drugs industry: global market expected to reach US $335.8 Billion in 2017 Irving, TX (PRWEB) May 14, 2013 Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The global generic drugs industry experienced average growth over the last five years and is expected to reach approximately US $335.8 billion in 2017. Lucintel,...
According to a new market report published by Transparency Market Research, "Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2013, the global computational biology market was valued at USD 760 million and is expected to grow at a CAGR of 21.3% from...
SOUTH SAN FRANCISCO, Calif., May 14, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer, announced today its financial results for the first quarter ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO) "KaloBios marked the first quarter of 2013...
MONTREAL, May 14, 2013 /PRNewswire/ -- Halo Pharma today announced that it has taken a minority ownership position in, and established a formal collaboration with, the drug formulation and development company Altus Formulation Inc. Altus uses proprietary technologies and approaches to solve pharmaceutical formulation and delivery problems. Halo is focused on satisfying the pharmaceutical client's development and manufacturing needs, whether those needs are straightforward or...
The announcement was made today by Pharmacist Partners, The Clinical Knowledge Organization(TM) (CKO). As a CKO, Pharmacist Partners utilizes pharmacists to provide education and advocacy to healthcare practitioners on behalf of its pharmaceutical clients. NEW YORK, May 14, 2013 /PRNewswire-iReach/ -- Mr. Castellani, one of the most respected visionaries in Corporate America, has been appointed to Pharmacist Partners' Advisory Board. Currently, Mr. Castellani leads PhRMA, an...
WASHINGTON, May 14, 2013 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Astellas Scientific and Medical Affairs, Inc. (Astellas), a U.S. affiliate of Tokyo-based Astellas Pharma Inc., has joined the health policy research organization as its newest member. Located in Northbrook, Illinois, Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable...
BOSTON, May 14, 2013 /PRNewswire/ -- On May 19-21 in Boston, clinical trial sponsors, CROs, sites and leaders from around the world will gather at the inaugural CenterWatch Forum on Optimizing Clinical Research Performance conference to discuss collaboration and innovation within a changing clinical trial research landscape. Among the clinical trial leaders in attendance will be AG Mednet CEO Abraham Gutman who will moderate a special program about successful site leadership and...
INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, underwent scheduled surgery for a dilated aorta on Monday, May 13, 2013. "Dr. Lechleiter's surgeons have advised us that surgery went as expected and the repair to the aorta is functioning as intended," said Kristine A. Courtney, M.D., senior director of Lilly's corporate health services. "Dr. Lechleiter is...
FREMONT, Calif., May 14, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the company's efforts in manufacturing, quality and engineering - vital activities to enable the company to accelerate the development of its...
Teleconference and Webcast to be held on Tuesday, May 14, 2013 CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013. The Company also summarized end-of-Phase 2 discussions with the U.S. Food and...
